Evidence map›Paper›PMID 41647477›Full record

ArticleiLIVER2026

Chemotherapy combined with pembrolizumab in advanced gallbladder cancer with subsequent radical resection: A case report.

Yongjie Hu, Yongpeng Wei, Xinbo Liu, Li Shen, Yu Wang, Jianyong Yuan

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in iLIVER, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Yongjie HuGeneral Surgery, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai 200437, China.
Yongpeng WeiDepartment of Hepatobiliary Surgery, Eastern Hepatobiliary Surgery Hospital, Naval Medical University, Shanghai 200438, China.
Xinbo LiuGeneral Surgery, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai 200437, China.
Li ShenGeneral Surgery, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai 200437, China.
Yu WangDepartment of Hepatobiliary Surgery, Eastern Hepatobiliary Surgery Hospital, Naval Medical University, Shanghai 200438, China.
Jianyong YuanGeneral Surgery, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai 200437, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Gallbladder cancer is often diagnosed at an advanced stage, preventing radical surgical intervention. Combined with its highly aggressive nature, this results in a generally poor prognosis. Although advancements in treatment strategies have expanded the application of conversion therapy for initially unresectable gallbladder cancer cases, achieving eligibility for radical resection remains uncommon. Here, we report a case of advanced gallbladder cancer where treatment with pembrolizumab combined with gemcitabine and cisplatin was followed by successful radical surgical resection, demonstrating a favorable therapeutic outcome. This case highlights the potential of combining immunotherapy and chemotherapy for improving treatment responses and surgical outcomes in advanced gallbladder cancer.

Indexed as

Conversion therapyGallbladder cancerPembrolizumab

Identifiers

PMID41647477
PMCPMC12870843

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.